Therefore, to figure out the impact of PAPPA2 mutation on the clinical outcome of ICIs treatment, we investigated the association between PAPPA2 mutation and clinical efficacy of ICI in several NSCLC and SKCM cohorts. Here, PAPPA2 is linked to non-small cell lung carcinoma.